# NIH Reporter #1R21AR088602-01

An Oleoyl Serine Derivative as an Innovative Therapeutic Approach for Osteoporosis

**Recipient:** Beth Israel Deaconess Medical Center, Boston, MA, United States

**Award Amount:** $430,816.00
**Ceiling:** $430,816.00

**Awarded:** September 17, 2026

**Identifier:** 1R21AR088602-01

Award for developing an oral nutraceutical compound to prevent osteoporosis-related bone loss in female mice, evaluating efficacy through various administration methods and bone health assessments.

### Description

This project aims to develop a safe, oral nutraceutical compound derived from olive oil, oleoyl -methyl serine (HU-671), to prevent osteoporosis-related bone loss in female mice. The study will evaluate the efficacy of HU-671 administered via oral gavage and intraperitoneal injection, assessing bone mass, microstructure, strength, and gene expression pathways.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11440446)